Asymchem Laboratories (Tianjin) Co.Ltd(002821) : Yang Rui, former chief operating officer, was appointed as co CEO

Asymchem Laboratories (Tianjin) Co.Ltd(002821) it was announced on January 19 that in order to further enhance the company’s global competitiveness in the small molecule cdmo industry, and quickly promote the development of cdmo business, an emerging drug category represented by chemical macromolecules and biological macromolecules, as well as clinical cro and other emerging service businesses, the company plans to adjust its organizational structure from functional structure to business division / group system, Establish chemical business group and strategic emerging business group, and add a co CEO. On January 19, 2022, the board of directors of the company designated Ms. Yang Rui, the former deputy general manager (chief operating officer) as the co CEO. The term of office starts from the date of deliberation and approval of the board of directors to the date of expiration of the Fourth Board of directors of the company. On the basis of continuing to support the operation of the whole group, Yang Rui will lead the development of the company’s strategic emerging business groups, including Asymchem Laboratories (Tianjin) Co.Ltd(002821) Biology (covering cdmo business in mAb, ADC, mRNA, ATMP and other fields), keno Pharmaceutical (clinical CRO), Tianjin Clinical Research Service Innovation Center (ticcr) and other business departments; Lead business development in emerging markets; Promote the business development of external application of new technologies such as nucleic acid drugs cdmo and continuous reaction, and promote the company’s investment layout around the world.